Hormonal
Tirzepatide treatment significantly reduces food cravings and preferences for energy-dense foods (high fat, high sugar, fast food fats) in people with obesity, independent of caloric restriction.
If you struggle with intense cravings for high-fat or high-sugar foods, tirzepatide can help reduce these urges. This isn't just about willpower; the medication physiologically lowers the 'pull' of these foods, making it easier to stick to a healthy diet.
In people with obesity, 18 weeks of treatment with tirzepatide resulted in significant decreases in food preferences and food cravings relative to placebo with dietary restriction.
Why this rating
Randomized controlled trial with a reasonable sample size (n=55), though secondary analysis and unadjusted p-values for multiple testing are limitations.
Source
Impact of tirzepatide treatment on participant‐reported food craving and food preference: Secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction
Sam F. Kennedy et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70063
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →